A phase II trial of docetaxel (Taxotere®) as second-line chemotherapy in patients with metastatic breast cancer

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Second Line ◽

Phase II trial of docetaxel and Herceptin (R) as first- or second-line chemotherapy for women with metastatic breast cancer whose tumours overexpress HER2

European Journal of Cancer ◽

10.1016/s0959-8049(99)81709-2 ◽

1999 ◽

Vol 35 ◽

pp. S322

Author(s):

H.A. Burris ◽

J.D. Hainesworth ◽

K. Albain ◽

M. Huntington ◽

F.A. Greco ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Second Line ◽

230 A Phase II Study of Pegylated Liposomal Doxorubicin Combined with Cyclophosphamide / 5-fluorouracil as Second Line Chemotherapy in Patients with Metastatic Breast Cancer Who Failed Previous Taxane-based Treatment

European Journal of Cancer ◽

10.1016/s0959-8049(12)70298-8 ◽

2012 ◽

Vol 48 ◽

pp. S109-S110

Author(s):

H.K. Chang ◽

Y.C. Lin ◽

K.M. Rau ◽

Y.Y. Chen ◽

K.D. Lee ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Metastatic Breast ◽

Pegylated Liposomal Doxorubicin ◽

Second Line ◽

A phase II, multicenter, single-arm trial of eribulin as first or second line chemotherapy for HER2-negative advanced or metastatic breast cancer: Evaluation of efficacy, safety, and patient-reported outcomes.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e13059 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e13059-e13059 ◽

Cited By ~ 2

Author(s):

Mitsuhiko Iwamoto ◽

Kosei Kimura ◽

Satoru Tanaka ◽

Daigo Yamamoto ◽

Katsuhide Yoshidome ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Patient Reported Outcomes ◽

Metastatic Breast ◽

Second Line ◽

Patient Reported ◽

Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions

Investigational New Drugs ◽

10.1007/s10637-007-9034-y ◽

2007 ◽

Vol 25 (4) ◽

pp. 369-375 ◽

Cited By ~ 26

Author(s):

Nancy U. Lin ◽

Leroy M. Parker ◽

Steven E. Come ◽

Harold J. Burstein ◽

Margaret Haldoupis ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Hypersensitivity Reactions ◽

Second Line ◽

A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-018-3567-y ◽

2018 ◽

Vol 81 (5) ◽

pp. 923-933

Author(s):

Kosei Kimura ◽

Mitsuhiko Iwamoto ◽

Satoru Tanaka ◽

Daigo Yamamoto ◽

Katsuhide Yoshidome ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Patient Reported Outcomes ◽

Metastatic Breast ◽

Second Line ◽

Patient Reported ◽

Abstract PS13-31: Prospective observational study to explore the effectiveness of eribulin as first- or second- line chemotherapy in patients with HER2-negative hormone-resistant advanced or metastatic breast cancer (KBCRN A001: E-SPEC study)

10.1158/1538-7445.sabcs20-ps13-31 ◽

2021 ◽

Author(s):

Yuri Fujimoto ◽

Yuichiro Kikawa ◽

Takeshi Kotake ◽

Shigeru Tsuyuki ◽

Sachiko Takahara ◽

...

Keyword(s):

Breast Cancer ◽

Observational Study ◽

Prospective Observational Study ◽

Metastatic Breast ◽

Second Line ◽

First-line chemotherapy of advanced or metastatic breast cancer (MBC) with docetaxel and doxorubicin in Indonesia: results from A phase II trial

Medical Journal of Indonesia ◽

10.13181/mji.v14i1.166 ◽

2005 ◽

pp. 20

Author(s):

Abdulmuthalib Abdulmuthalib ◽

Idral Darwis ◽

Nugroho Prayogo ◽

Sutjipto Sutjipto

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

First Line ◽

Cost-Effectiveness Analysis of Fulvestrant in the Treatment of Metastatic Breast Cancer in Second-Line Chemotherapy

Value in Health ◽

10.1016/j.jval.2014.08.2289 ◽

2014 ◽

Vol 17 (7) ◽

pp. A637

Author(s):

I. Krysanov ◽

V. Krysanova

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Cost Effectiveness Analysis ◽

Second Line ◽

Effectiveness Analysis ◽

Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2013.02.008 ◽

2013 ◽

Vol 13 (4) ◽

pp. 239-246.e1 ◽

Cited By ~ 19

Author(s):

Andrew D. Seidman ◽

Alison K. Conlin ◽

Ariadne Bach ◽

Mary Ellen Moynahan ◽

Diana Lake ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

First Line ◽

Randomized Phase Ii ◽

Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial

BMC Cancer ◽

10.1186/s12885-018-4628-7 ◽

2018 ◽

Vol 18 (1) ◽

Cited By ~ 3

Author(s):

Tetsu Hayashida ◽

Hiromitsu Jinno ◽

Katsuaki Mori ◽

Hiroki Sato ◽

Akira Matsui ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Metastatic Breast ◽

Line Treatment ◽

Second Line ◽

Eribulin Mesylate